Investigational Site Number 840102

Washington D.C., District of Columbia 20016-2695

0 studies enrolling now · 1 studies all time

What they study most

Prostate Cancer Metastatic

Studies at this site

• Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Completed